Genesis IBRC (514336)

Score breakdown: P/E: 0/3 · ROCE: 2/2 · Growth: 0/2 · Dividend: 0/1

Key Financials

Strengths

• Reported ROCE of 51.62% suggests the existing capital base has been productive, if the figure is sustainable.
• Book value per share is positive at ₹5.72, providing some tangible cushion.
• Small market cap of ₹98 Cr leaves theoretical room for growth if operations restart.
• Current price is far below the 52-week high of ₹181.30, so much speculative froth has already been removed.

Concerns

• Latest quarter shows sales of ₹0 Cr and net profit of ₹-0 Cr, indicating no active revenue generation.
• ROE is -2.76%, so shareholder equity is not earning its keep.
• P/B of 2.64 means paying a 164% premium to book value for a company with zero earnings and no dividend.
• Piotroski F-score of 3/9 signals weak financial health; promoter holding and debt details are unknown.

AI Analysis

At first glance, Genesis IBRC is exactly the kind of small-cap biotech that tempts a speculator, not an investor. Price ₹15.10, market cap ₹98 Cr. But the latest quarter shows sales of ₹0 Cr and net profit of ₹-0 Cr. You cannot put a P/E on a company that earns nothing. As Graham said, the stock market is a voting machine in the short run and a weighing machine in the long run; right now there is nothing being weighed. ROE is -2.76%, meaning the business is destroying shareholder value. The Piotroski F-score is a weak 3/9, so the financial situation is fragile. I note ROCE of 51.62%, but with zero sales and negligible profit, I would treat that ratio as an anomaly rather than a moat. If I cannot understand where revenue comes from, I cannot value the business. Book value is ₹5.72, yet I am asked to pay ₹15.10, or 2.64 times book. There is no dividend, no growth, and no promoter holding data. The 52-week range of ₹34.51 to ₹181.30 shows how wild the ride has been; at ₹15.10, it is even below that range, a red flag in itself. This is not an asset play because the price is above book. It is not a growing business because there is no sales. It could only be a turnaround if operations resume, but I have no evidence that they will. Without a margin of safety, I cannot invest. I would put this in the 'too hard' pile and move on.

Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer